Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

This is mainly an uncertainty-removal event rather than a clear earnings upgrade. ASND should get the bigger multiple benefit because litigation overhangs tend to compress biotech EV/revenue multiples until the market can model commercialization without a headline risk discount; the immediate reaction is likely to be relief-driven, but the durability depends on whether the settlement preserves economics or merely buys peace at a price.

The second-order issue is that a global license deal can quietly redistribute value: any cash payment, royalty, field restriction, or inventory/launch constraint would shift future margin from ASND to BMRN without showing up in near-term revenue optics. For BMRN, the best-case outcome is lower legal expense and fewer distraction costs; the worse case is that it has effectively conceded a strategically important asset and may face scrutiny if the asset was expected to support pipeline optionality.

Over the next 1-3 months, the key catalyst is the actual filing or disclosed terms. If the agreement includes modest consideration and preserves commercial flexibility, ASND could see a re-rate as a cleaner story; if terms are punitive, the initial pop should fade quickly. Over 6-18 months, the thesis turns on whether this removes a structural overhang on partnership appetite and investor willingness to underwrite the asset base as more durable.

Contrarian read: consensus may be treating “settlement” as uniformly positive, but in biotech these deals often transfer value in ways that are easy to miss in the headline. Until the economics are public, the right posture is to assume the market is pricing in too much certainty and to wait for the filing before leaning aggressively either way.